Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD63 | P08962 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 10/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30310838 | 0.87 | MAPT (0.41) | KDM4CGAAMAPTSMN1; SMN2MEN1 | |
| SCHEMBL30202722 | 0.85 | KDM4C (0.33) | CD63SYKKDM4CGAAMAPT | |
| SCHEMBL30029737 | 0.84 | ALDH1A1 (0.40) | MAPTSMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL16851816 | 0.84 | ALDH1A1 (0.40) | MAPTSMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL30310855 | 0.81 | KDM4C (0.36) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL20344872 | 0.80 | SYK (0.52) | CD63SYKTBK1GAAMAPT | |
| SCHEMBL16848693 | 0.80 | CD63 (0.43) | CD63SYKTBK1GAAMAPT | |
| SCHEMBL24904153 | 0.78 | BRAF (0.42) | CD63SYKGAAMAPTSMN1; SMN2 | |
| SCHEMBL16851817 | 0.76 | SYK (0.56) | CD63SYKJAK2 | |
| SCHEMBL17440409 | 0.75 | CD63 (0.33) | CD63SYKKDM4CTBK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12263163-B2 | Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor | Kronos Bio, Inc. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20230158023-A1 | CRYSTALLINE SUCCINATE SALT OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-AMINE | GILEAD SCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158023-A1 | CRYSTALLINE SUCCINATE SALT OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-AMINE | GILEAD SCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11517570-B2 | Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine | Kronos Bio, Inc. (US) | 2022-12-06 | — | — | US | disclosed |
| US-11517570-B2 | Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine | Kronos Bio, Inc. (US) | 2022-12-06 | — | — | US | disclosed |
| EP-3342773-B9 | SYK INHIBITORS | KRONOS BIO INC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20210060011-A1 | CRYSTALLINE MONOMESYLATE SALT OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-AMINE | Kronos Bio, Inc. | 2021-03-04 | — | — | US | disclosed |
| EP-3342773-B1 | SYK INHIBITORS | GILEAD SCIENCES INC (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10828299-B2 | Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine | Kronos Bio, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10342794-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-9968601-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9931338-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| EP-3087075-B1 | SYK INHIBITORS | GILEAD SCIENCES INC (US) | 2018-02-14 | — | — | EP | disclosed |
| US-20170035755-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2017-02-09 | — | — | US | disclosed |
| US-9504684-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| WO-2016172117-A1 | TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE WITH SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| US-20160310490-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-10-27 | — | — | US | disclosed |
| US-9290505-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160058758-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-03-03 | — | — | US | disclosed |
| US-20150175616-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11517570-B2 | Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine | SYK, LCK, LYN | CD63 3157/4885SYK 1/4885KDM4C 549/4885 |
| US-20230158023-A1 | CRYSTALLINE SUCCINATE SALT OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-AMINE | SYK, LCK, LYN | CD63 3157/4885SYK 1/4885KDM4C 549/4885 |
| US-20170035755-A1 | SYK INHIBITORS | SYK, BTK, LYN | CD63 2809/4885SYK 1/4885KDM4C 779/4885 |
| US-12263163-B2 | Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor | SYK, LCK, LYN | CD63 3342/4885SYK 1/4885KDM4C 612/4885 |
| US-20150175616-A1 | SYK INHIBITORS | SYK, BTK, LYN | CD63 2113/4885SYK 1/4885KDM4C 905/4885 |
| US-10828299-B2 | Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine | SYK, LYN, BTK | CD63 3094/4885SYK 1/4885KDM4C 579/4885 |
| US-10342794-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | SYK, BTK, LYN | CD63 2843/4885SYK 1/4885KDM4C 1034/4885 |
| US-20160310490-A1 | SYK INHIBITORS | SYK, BTK, LYN | CD63 2113/4885SYK 1/4885KDM4C 905/4885 |
| US-20210060011-A1 | CRYSTALLINE MONOMESYLATE SALT OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-AMINE | SYK, LYN, BTK | CD63 3094/4885SYK 1/4885KDM4C 579/4885 |
| US-20160058758-A1 | SYK INHIBITORS | SYK, BTK, LYN | CD63 2809/4885SYK 1/4885KDM4C 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.